{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:44:13Z","timestamp":1792014253875,"version":"4.4.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40263-026-01330-8","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:43:00Z","timestamp":1787733780000},"page":"1429-1444","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II\/III Drug Development Across Diverse Mechanisms"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4650-0017","authenticated-orcid":false,"given":"Alana","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4248-4106","authenticated-orcid":false,"given":"Morgan","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4961-3361","authenticated-orcid":false,"given":"Taeho Greg","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3483-9168","authenticated-orcid":false,"given":"Samuel T.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"issue":"10","key":"1330_CR1","doi-asserted-by":"publisher","first-page":"4460","DOI":"10.1007\/s12325-023-02622-x","volume":"40","author":"P Greenberg","year":"2019","unstructured":"Greenberg P, Chitnis A, Louie D, Suthoff E, Chen S-Y, Maitland J, et al. The economic burden of adults with major depressive disorder in the United States (2019). Adv Ther. 2019;40(10):4460\u201379. https:\/\/doi.org\/10.1007\/s12325-023-02622-x.","journal-title":"Adv Ther"},{"issue":"6","key":"1330_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40273-021-01019-4","volume":"39","author":"PE Greenberg","year":"2010","unstructured":"Greenberg PE, Fournier AA, Sisitsky T, Simes M, Berman R, Koenigsberg SH, et al. The economic burden of adults with major depressive disorder in the United States (2010 and 2018). Pharmacoeconomics. 2010;39(6):653\u201365. https:\/\/doi.org\/10.1007\/s40273-021-01019-4.","journal-title":"Pharmacoeconomics"},{"key":"1330_CR3","unstructured":"Anxiety and Depression Association of America. Anxiety disorders: facts & statistics. 2025. https:\/\/adaa.org\/understanding-anxiety\/facts-statistics. Accessed 14 Jul 2026."},{"key":"1330_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2147\/ndt.S198774","volume":"16","author":"D Voineskos","year":"2020","unstructured":"Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. 2020;16:221\u201334. https:\/\/doi.org\/10.2147\/ndt.S198774.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1330_CR5","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212290","volume":"4","author":"D Santarsieri","year":"2015","unstructured":"Santarsieri D, Schwartz TL. Antidepressant efficacy and side-effect burden: a quick guide for clinicians. Drugs Context. 2015;4:212290. https:\/\/doi.org\/10.7573\/dic.212290.","journal-title":"Drugs Context."},{"issue":"1","key":"1330_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4088\/pcc.v03n0105","volume":"3","author":"JM Ferguson","year":"2001","unstructured":"Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry. 2001;3(1):22\u20137. https:\/\/doi.org\/10.4088\/pcc.v03n0105.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"9","key":"1330_CR7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","volume":"76","author":"EJ Daly","year":"2019","unstructured":"Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiat. 2019;76(9):893\u2013903. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.1189.","journal-title":"JAMA Psychiat"},{"issue":"10152","key":"1330_CR8","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/s0140-6736(18)31551-4","volume":"392","author":"S Meltzer-Brody","year":"2018","unstructured":"Meltzer-Brody S, Colquhoun H, Riesenberg R, Epperson CN, Deligiannidis KM, Rubinow DR, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet. 2018;392(10152):1058\u201370. https:\/\/doi.org\/10.1016\/s0140-6736(18)31551-4.","journal-title":"Lancet"},{"issue":"9","key":"1330_CR9","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1176\/appi.ajp.20220459","volume":"180","author":"AH Clayton","year":"2023","unstructured":"Clayton AH, Lasser R, Parikh SV, Iosifescu DV, Jung J, Kotecha M, et al. Zuranolone for the treatment of adults with major depressive disorder: a randomized, placebo-controlled phase 3 trial. Am J Psychiatry. 2023;180(9):676\u201384. https:\/\/doi.org\/10.1176\/appi.ajp.20220459.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1330_CR10","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/02698811231158891","volume":"37","author":"T Cooper","year":"2023","unstructured":"Cooper T, Seigler MD, Stahl S. Rapid onset brain plasticity at novel pharmacologic targets hypothetically drives innovations for rapid onset antidepressant actions. J Psychopharmacol. 2023;37(3):242\u20137. https:\/\/doi.org\/10.1177\/02698811231158891.","journal-title":"J Psychopharmacol"},{"issue":"12","key":"1330_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103818","volume":"28","author":"TG Rhee","year":"2023","unstructured":"Rhee TG, Davoudian PA, Sanacora G, Wilkinson ST. Psychedelic renaissance: revitalized potential therapies for psychiatric disorders. Drug Discov Today. 2023;28(12):103818. https:\/\/doi.org\/10.1016\/j.drudis.2023.103818.","journal-title":"Drug Discov Today"},{"key":"1330_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1196\/annals.1418.005","volume":"1144","author":"MP Mattson","year":"2008","unstructured":"Mattson MP. Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y Acad Sci. 2008;1144:97\u2013112. https:\/\/doi.org\/10.1196\/annals.1418.005.","journal-title":"Ann N Y Acad Sci"},{"issue":"11","key":"1330_CR13","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.biopsych.2007.03.017","volume":"62","author":"K Hashimoto","year":"2007","unstructured":"Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry. 2007;62(11):1310\u20136. https:\/\/doi.org\/10.1016\/j.biopsych.2007.03.017.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"1330_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.64719\/pb.4260","volume":"35","author":"HK Manji","year":"2001","unstructured":"Manji HK, Duman RS. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull. 2001;35(2):5\u201349.","journal-title":"Psychopharmacol Bull"},{"issue":"5","key":"1330_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3109\/10673229.2010.511059","volume":"18","author":"C Zarate Jr","year":"2010","unstructured":"Zarate C Jr, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, Salvadore G. Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry. 2010;18(5):293\u2013303. https:\/\/doi.org\/10.3109\/10673229.2010.511059.","journal-title":"Harv Rev Psychiatry"},{"key":"1330_CR16","unstructured":"Neurocrine Biosciences. Neurocrine biosciences presents positive new data from Phase 2 study of osavampator in adults with major depressive disorder. 2025. https:\/\/neurocrine.gcs-web.com\/news-releases\/news-release-details\/neurocrine-biosciences-presents-positive-new-data-phase-2-study. Accessed 14 Jul 2026."},{"key":"1330_CR17","unstructured":"Neurocrine Biosciences. Neurocrine biosciences provides update on Phase 2 study of NBI-1070770 in adults with major depressive disorder. 2025. https:\/\/neurocrine.gcs-web.com\/news-releases\/news-release-details\/neurocrine-biosciences-provides-update-phase-2-study-nbi-1070770. Accessed 14 Jul 2026."},{"key":"1330_CR18","unstructured":"Gilgamesh Pharma. Gilgamesh Pharma announces positive topline Phase 2a results for blixeprodil (GM-1020) in major depressive disorder. 2026. https:\/\/www.prnewswire.com\/news-releases\/gilgamesh-pharma-announces-positive-topline-phase-2a-results-for-blixeprodil-gm-1020-in-major-depressive-disorder-302653958.html. Accessed 14 Jul 2026."},{"key":"1330_CR19","unstructured":"Sanacora G, Franco DC, Feldberg A, Fowler CJ, Goelder RG, Starling B. Efficacy and safety of an NR2B NAM, BI 1569912, as monotherapy in people living with major depressive disorder: results from a Phase II clinical trial. Presented at: American College of Neuropsychopharmacology Annual Meeting; January 12\u201315, 2026; Nassau, Bahamas. https:\/\/www.nature.com\/articles\/s41386-025-02281-2. Accessed 14 Jul 2026."},{"key":"1330_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0000000000002171","author":"A Merola","year":"1942","unstructured":"Merola A, Mukai Y, Bueters T, Ceesay P, Dupre N, Furtek C, et al. Phase 2 clinical trial of MK-1942, a negative allosteric modulator of metabotropic glutamate receptor 2, for treatment-resistant depression. J Clin Psychopharmacol. 1942. https:\/\/doi.org\/10.1097\/jcp.0000000000002171.","journal-title":"J Clin Psychopharmacol"},{"key":"1330_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105682","volume":"169","author":"S Chen","year":"2021","unstructured":"Chen S, Gao L, Li X, Ye Y. Allopregnanolone in mood disorders: mechanism and therapeutic development. Pharmacol Res. 2021;169:105682. https:\/\/doi.org\/10.1016\/j.phrs.2021.105682.","journal-title":"Pharmacol Res"},{"issue":"3","key":"1330_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40263-021-00885-y","volume":"36","author":"S Costi","year":"2022","unstructured":"Costi S, Han M-H, Murrough JW. The potential of KCNQ potassium channel openers as novel antidepressants. CNS Drugs. 2022;36(3):207\u201316. https:\/\/doi.org\/10.1007\/s40263-021-00885-y.","journal-title":"CNS Drugs"},{"key":"1330_CR23","unstructured":"Xenon Pharmaceuticals. Xenon Pharmaceuticals presents data from Phase 2 X-NOVA clinical trial of azetukalner in major depressive disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting. 2024. https:\/\/investor.xenon-pharma.com\/news-releases\/news-release-details\/xenon-pharmaceuticals-presents-data-phase-2-x-nova-clinical. Accessed 14 Jul 2026."},{"key":"1330_CR24","unstructured":"Biohaven Pharmaceuticals. Biohaven provides update from Phase 2 proof-of-concept study with BHV-7000 in major depressive disorder. 2025. https:\/\/www.prnewswire.com\/news-releases\/biohaven-provides-update-from-phase-2-proof-of-concept-study-with-bhv-7000-in-major-depressive-disorder-302649251.html. Accessed 14 Jul 2026."},{"key":"1330_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/7854_2017_478","volume":"36","author":"JF L\u00f3pez-Gim\u00e9nez","year":"2018","unstructured":"L\u00f3pez-Gim\u00e9nez JF, Gonz\u00e1lez-Maeso J. Hallucinogens and serotonin 5-HT(2A) receptor-mediated signaling pathways. Curr Top Behav Neurosci. 2018;36:45\u201373. https:\/\/doi.org\/10.1007\/7854_2017_478.","journal-title":"Curr Top Behav Neurosci"},{"issue":"4","key":"1330_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmr.2025.100059","volume":"77","author":"BR Cummins","year":"2025","unstructured":"Cummins BR, Billac GB, Nichols DE, Nichols CD. 5-HT2A receptors: pharmacology and functional selectivity. Pharmacol Rev. 2025;77(4):100059. https:\/\/doi.org\/10.1016\/j.pharmr.2025.100059.","journal-title":"Pharmacol Rev"},{"issue":"2","key":"1330_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/cpt.557","volume":"101","author":"D Nichols","year":"2017","unstructured":"Nichols D, Johnson M, Nichols C. Psychedelics as medicines: an emerging new paradigm. Clin Pharmacol Ther. 2017;101(2):209\u201319. https:\/\/doi.org\/10.1002\/cpt.557.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"1330_CR28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30214","volume":"14","author":"DB Goel","year":"2022","unstructured":"Goel DB, Zilate S. Potential therapeutic effects of psilocybin: a systematic review. Cureus. 2022;14(10):e30214. https:\/\/doi.org\/10.7759\/cureus.30214.","journal-title":"Cureus"},{"issue":"3","key":"1330_CR29","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.euroneuro.2013.12.006","volume":"24","author":"F Tyl\u0161","year":"2014","unstructured":"Tyl\u0161 F, P\u00e1len\u00ed\u010dek T, Hor\u00e1\u010dek J. Psilocybin\u2014summary of knowledge and new perspectives. Eur Neuropsychopharmacol. 2014;24(3):342\u201356. https:\/\/doi.org\/10.1016\/j.euroneuro.2013.12.006.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"18","key":"1330_CR30","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387(18):1637\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2206443.","journal-title":"N Engl J Med"},{"key":"1330_CR31","unstructured":"Compass Pathways. Compass pathways successfully achieves primary endpoint in first Phase 3 trial evaluating COMP360 psilocybin for treatment-resistant depression. 2025. https:\/\/ir.compasspathways.com\/News--Events-\/news\/news-details\/2025\/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression\/default.aspx. Accessed 14 Jul 2026."},{"key":"1330_CR32","unstructured":"Compass Pathways. Compass pathways successfully achieves primary endpoint in second Phase 3 trial evaluating COMP360 psilocybin for treatment-resistant depression. 2026. https:\/\/ir.compasspathways.com\/News--Events-\/news\/news-details\/2026\/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-Second-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression\/default.aspx. Accessed 14 Jul 2026."},{"issue":"9","key":"1330_CR33","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA. 2023;330(9):843\u201353. https:\/\/doi.org\/10.1001\/jama.2023.14530.","journal-title":"JAMA"},{"key":"1330_CR34","unstructured":"Beckley Psytech. Beckley Psytech announces positive topline results from Phase IIa study of ELE-101 (IV psilocin benzoate) for major depressive disorder. 2024. https:\/\/www.beckleypsytech.com\/posts\/beckley-psytech-announces-positive-topline-results-from-phase-iia-study-of-ele-101-for-major-depressive-disorder. Accessed 14 Jul 2026."},{"key":"1330_CR35","unstructured":"Krempien S, Inamdar A, Shenouda M, Johnson K, Maass-Robinson S, Johnson M, et al. Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of CYB-003, a deuterated psilocybin analog in patients with major depressive disorder. Presented at: American College of Neuropsychopharmacology Annual Meeting; December 3, 2023; Whistler, BC, Canada. https:\/\/www.helus.com\/wp-content\/uploads\/2025\/04\/m83-2023-CYB003-Krempien-Randomized-Double-blind-Placebo-Controlled-Study-to-Evaluate-the-Safety-and-Efficacy-of-CYB003.pdf. Accessed 14 Jul 2026."},{"issue":"4","key":"1330_CR36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","volume":"14","author":"T Passie","year":"2008","unstructured":"Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther. 2008;14(4):295\u2013314. https:\/\/doi.org\/10.1111\/j.1755-5949.2008.00059.x.","journal-title":"CNS Neurosci Ther"},{"key":"1330_CR37","unstructured":"Definium Therapeutics. Definium therapeutics announces positive topline results from Phase 3 emerge study of DT120 orally disintegrating tablet (ODT) in major depressive disorder. 2026. https:\/\/ir.definiumtx.com\/news-events\/press-releases\/detail\/232\/definium-therapeutics-announces-positive-topline-results-from-phase-3-emerge-study-of-dt120-orally-disintegrating-tablet-odt-in-major-depressive-disorder. Accessed 14 Jul 2026."},{"issue":"Pt 1","key":"1330_CR38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.brainresbull.2016.04.016","volume":"126","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro TM, Gatch MB. Neuropharmacology of N,N-dimethyltryptamine. Brain Res Bull. 2016;126(Pt 1):74\u201388. https:\/\/doi.org\/10.1016\/j.brainresbull.2016.04.016.","journal-title":"Brain Res Bull"},{"issue":"3","key":"1330_CR39","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","volume":"53","author":"J Gonz\u00e1lez-Maeso","year":"2007","unstructured":"Gonz\u00e1lez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron. 2007;53(3):439\u201352. https:\/\/doi.org\/10.1016\/j.neuron.2007.01.008.","journal-title":"Neuron"},{"issue":"1","key":"1330_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-01011-0","volume":"10","author":"JA Morales-Garcia","year":"2020","unstructured":"Morales-Garcia JA, Calleja-Conde J, Lopez-Moreno JA, Alonso-Gil S, Sanz-SanCristobal M, Riba J, et al. N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo. Transl Psychiatry. 2020;10(1):331. https:\/\/doi.org\/10.1038\/s41398-020-01011-0.","journal-title":"Transl Psychiatry"},{"issue":"1","key":"1330_CR41","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/jnc.15587","volume":"162","author":"JT Reckweg","year":"2022","unstructured":"Reckweg JT, Uthaug MV, Szabo A, Davis AK, Lancelotta R, Mason NL, et al. The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). J Neurochem. 2022;162(1):128\u201346. https:\/\/doi.org\/10.1111\/jnc.15587.","journal-title":"J Neurochem"},{"issue":"2","key":"1330_CR42","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/00952990.2018.1545024","volume":"45","author":"AK Davis","year":"2019","unstructured":"Davis AK, So S, Lancelotta R, Barsuglia JP, Griffiths RR. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. Am J Drug Alcohol Abuse. 2019;45(2):161\u20139. https:\/\/doi.org\/10.1080\/00952990.2018.1545024.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"1330_CR43","unstructured":"GH Research. GH research announces primary endpoint met in Phase 2b trial with GH001 in TRD demonstrating -15.5 point placebo-adjusted MADRS reduction. 2025. https:\/\/investor.ghres.com\/news-releases\/news-release-details\/gh-research-announces-primary-endpoint-met-phase-2b-trial-gh001. Accessed 14 Jul 2026."},{"issue":"6","key":"1330_CR44","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jamapsychiatry.2026.0096","volume":"83","author":"WJ Cuba\u0142a","year":"2026","unstructured":"Cuba\u0142a WJ, Bajbouj M, Bauer M, Baune BT, Cardoner N, Devlin F, et al. GH001 vs placebo in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiat. 2026;83(6):561\u20139. https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.0096.","journal-title":"JAMA Psychiat"},{"key":"1330_CR45","unstructured":"GH Research. GH research announces FDA lifts clinical hold on GH001, clearing path for global Phase 3 initiation in 2026. 2026. https:\/\/investor.ghres.com\/news-releases\/news-release-details\/gh-research-announces-fda-lifts-clinical-hold-gh001-clearing\/. Accessed 14 Jul 2026."},{"key":"1330_CR46","doi-asserted-by":"publisher","DOI":"10.1177\/02698811261420087","author":"C Roberts","year":"2026","unstructured":"Roberts C, Seynaeve M, Ermakova AO, Dunbar F, Wells H, Puri A, et al. A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression. J Psychopharmacol. 2026. https:\/\/doi.org\/10.1177\/02698811261420087.","journal-title":"J Psychopharmacol"},{"key":"1330_CR47","unstructured":"AtaiBeckley. Atai Life Sciences and Beckley Psytech announce positive topline results from the Phase 2b study of BPL-003 in patients with treatment-resistant depression. 2025. https:\/\/ir.atai.com\/news-releases\/news-release-details\/atai-life-sciences-and-beckley-psytech-announce-positive-topline. Accessed 14 Jul 2026."},{"key":"1330_CR48","unstructured":"Gilgamesh Pharmaceuticals. Gilgamesh Pharmaceuticals announces positive topline Phase 2a results for GM-2505 in major depressive disorder (MDD). 2025. https:\/\/www.prnewswire.com\/news-releases\/gilgamesh-pharmaceuticals-announces-positive-topline-phase-2a-results-for-gm-2505-in-major-depressive-disorder-mdd-302465404.html. Accessed 14 Jul 2026."},{"issue":"6","key":"1330_CR49","doi-asserted-by":"publisher","first-page":"739","DOI":"10.2174\/1570159x13666150612230045","volume":"13","author":"WJ Jeon","year":"2015","unstructured":"Jeon WJ, Dean B, Scarr E, Gibbons A. The role of muscarinic receptors in the pathophysiology of mood disorders: a potential novel treatment? Curr Neuropharmacol. 2015;13(6):739\u201349. https:\/\/doi.org\/10.2174\/1570159x13666150612230045.","journal-title":"Curr Neuropharmacol"},{"key":"1330_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.861094","volume":"13","author":"M Alhusaini","year":"2022","unstructured":"Alhusaini M, Eissa N, Saad AK, Beiram R, Sadek B. Revisiting preclinical observations of several histamine H3 receptor antagonists\/inverse agonists in cognitive impairment, anxiety, depression, and sleep-wake cycle disorder. Front Pharmacol. 2022;13:861094. https:\/\/doi.org\/10.3389\/fphar.2022.861094.","journal-title":"Front Pharmacol"},{"key":"1330_CR51","unstructured":"Alto Neuroscience. Alto neuroscience identifies biomarker and reports positive pharmacodynamic results from exploratory Phase 2 proof-of-concept trial of ALTO-203. 2025. https:\/\/investors.altoneuroscience.com\/news\/news-details\/2025\/Alto-Neuroscience-Identifies-Biomarker-and-Reports-Positive-Pharmacodynamic-Results-from-Exploratory-Phase-2-Proof-of-Concept-Trial-of-ALTO-203\/default.aspx. Accessed 14 Jul 2026."},{"key":"1330_CR52","unstructured":"Alto Neuroscience. Alto Neuroscience announces positive results from Phase 2 study of ALTO-300 in major depressive disorder. 2023. https:\/\/investors.altoneuroscience.com\/news\/news-details\/2023\/Alto-Neuroscience-Announces-Positive-Results-from-Phase-2-Study-of-ALTO-300-in-Major-Depressive-Disorder-12-04-2023\/default.aspx. Accessed 14 Jul 2026."},{"key":"1330_CR53","unstructured":"Alto Neuroscience. Alto Neuroscience reports topline results from a Phase 2b trial evaluating ALTO-100 as a treatment for major depressive disorder. 2024. https:\/\/investors.altoneuroscience.com\/news\/news-details\/2024\/Alto-Neuroscience-Reports-Topline-Results-from-a-Phase-2b-Trial-Evaluating-ALTO-100-as-a-Treatment-for-Major-Depressive-Disorder\/default.aspx. Accessed 14 Jul 2026."},{"key":"1330_CR54","unstructured":"Alto Neuroscience. Alto Neuroscience announces acquisition of novel dopamine agonist combination product candidate, adding late-stage readout in treatment resistant depression within current cash runway. 2025. https:\/\/investors.altoneuroscience.com\/news\/news-details\/2025\/Alto-Neuroscience-Announces-Acquisition-of-Novel-Dopamine-Agonist-Combination-Product-Candidate-Adding-Late-Stage-Readout-in-Treatment-Resistant-Depression-Within-Current-Cash-Runway\/default.aspx. Accessed 14 Jul 2026."},{"key":"1330_CR55","unstructured":"Alto Neuroscience. Alto Neuroscience announces plans to accelerate development of ALTO-207 in treatment resistant depression following successful outcome from recent FDA meeting. 2025. https:\/\/investors.altoneuroscience.com\/news\/news-details\/2025\/Alto-Neuroscience-Announces-Plans-to-Accelerate-Development-of-ALTO-207-in-Treatment-Resistant-Depression-Following-Successful-Outcome-from-Recent-FDA-Meeting\/default.aspx. Accessed 14 Jul 2026."},{"issue":"6","key":"1330_CR56","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1172\/jci129702","volume":"129","author":"Y Hasegawa","year":"2019","unstructured":"Hasegawa Y, Zhu X, Kamiya A. NV-5138 as a fast-acting antidepressant via direct activation of mTORC1 signaling. J Clin Invest. 2019;129(6):2207\u20139. https:\/\/doi.org\/10.1172\/jci129702.","journal-title":"J Clin Invest"},{"key":"1330_CR57","unstructured":"Supernus Pharmaceuticals. Supernus presents promising data from open-label Phase 2a study of SPN-820 data in major depressive disorder at Psych Congress 2024. 2024. https:\/\/ir.supernus.com\/news-releases\/news-release-details\/supernus-presents-promising-data-open-label-phase-2a-study-spn. Accessed 14 Jul 2026."},{"key":"1330_CR58","unstructured":"Supernus Pharmaceuticals. Supernus announces topline results from Phase 2b study in adults with treatment resistant depression. 2025. https:\/\/ir.supernus.com\/news-releases\/news-release-details\/supernus-announces-topline-results-phase-2b-study-adults. Accessed 14 Jul 2026."},{"issue":"6","key":"1330_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12061263","volume":"12","author":"TS Shemiakova","year":"2024","unstructured":"Shemiakova TS, Efimova EV, Gainetdinov RR. TAARs as novel therapeutic targets for the treatment of depression: a narrative review of the interconnection with monoamines and adult neurogenesis. Biomedicines. 2024;12(6):1263. https:\/\/doi.org\/10.3390\/biomedicines12061263.","journal-title":"Biomedicines"},{"issue":"3","key":"1330_CR60","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s43440-020-00097-z","volume":"72","author":"J Kryst","year":"2020","unstructured":"Kryst J, Kawalec P, Mitoraj AM, Pilc A, Laso\u0144 W, Brzostek T. Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. Pharmacol Rep. 2020;72(3):543\u201362. https:\/\/doi.org\/10.1007\/s43440-020-00097-z.","journal-title":"Pharmacol Rep"},{"issue":"12","key":"1330_CR61","doi-asserted-by":"publisher","first-page":"e2449026","DOI":"10.1001\/jamanetworkopen.2024.49026","volume":"7","author":"AL Back","year":"2024","unstructured":"Back AL, Freeman-Young TK, Morgan L, Sethi T, Baker KK, Myers S, et al. Psilocybin therapy for clinicians with symptoms of depression from frontline care during the COVID-19 pandemic: a randomized clinical trial. JAMA Netw Open. 2024;7(12):e2449026. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.49026.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"1330_CR62","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamapsychiatry.2025.4809","volume":"83","author":"ZJ Williams","year":"2026","unstructured":"Williams ZJ, Barnett H, Szigeti B. Psychedelic therapy vs antidepressants for the treatment of depression under equal unblinding conditions: a systematic review and meta-analysis. JAMA Psychiat. 2026;83(5):461\u20138. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.4809.","journal-title":"JAMA Psychiat"},{"key":"1330_CR63","unstructured":"U.S. Food and Drug Administration. Psychedelic drugs: considerations for clinical investigations. Draft Guidance for Industry. Silver Spring, MD: Center for Drug Evaluation and Research, U.S. Food and Drug Administration; 2023. https:\/\/www.fda.gov\/media\/169694\/download. Accessed 14 Jul 2026."},{"issue":"15","key":"1330_CR64","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1001\/jama.2025.13481","volume":"334","author":"R Robison","year":"2025","unstructured":"Robison R, Barrow R, Conant C, Foster E, Freedman JM, Jacobsen PL, et al. Single treatment with MM120 (Lysergide) in generalized anxiety disorder: a randomized clinical trial. JAMA. 2025;334(15):1358\u201372. https:\/\/doi.org\/10.1001\/jama.2025.13481.","journal-title":"JAMA"},{"issue":"6","key":"1330_CR65","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1515\/revneuro-2015-0066","volume":"27","author":"A Rubio-Casillas","year":"2016","unstructured":"Rubio-Casillas A, Fern\u00e1ndez-Guasti A. The dose makes the poison: from glutamate-mediated neurogenesis to neuronal atrophy and depression. Rev Neurosci. 2016;27(6):599\u2013622. https:\/\/doi.org\/10.1515\/revneuro-2015-0066.","journal-title":"Rev Neurosci"},{"issue":"1","key":"1330_CR66","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/02698811211044688","volume":"36","author":"RF Leger","year":"2022","unstructured":"Leger RF, Unterwald EM. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: a systematic review and meta-analysis. J Psychopharmacol. 2022;36(1):20\u201330. https:\/\/doi.org\/10.1177\/02698811211044688.","journal-title":"J Psychopharmacol"},{"issue":"5","key":"1330_CR67","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/jamapsychiatry.2026.0132","volume":"83","author":"LJ Mertens","year":"2026","unstructured":"Mertens LJ, Koslowski M, Betzler F, Brand M, Evens R, K\u00e4rtner L, et al. Efficacy and safety of psilocybin in treatment-resistant major depression: the EPISODE randomized clinical trial. JAMA Psychiat. 2026;83(5):448\u201360. https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.0132.","journal-title":"JAMA Psychiat"},{"key":"1330_CR68","unstructured":"National Institute of Mental Health. Major depression. 2023. https:\/\/www.nimh.nih.gov\/health\/statistics\/major-depression. Accessed 28 Jul 2026."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01330-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01330-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01330-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:44:27Z","timestamp":1792010667000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01330-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1330"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01330-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.K. was responsible for conceptualization, data curation, formal analysis, writing the original draft, and writing\u2014review andediting. S.W. contributed to conceptualization, supervision, and writing\u2014review and editing. M.H. contributed toconceptualization and writing\u2014review and editing. T.G.R. contributed to methodology, data analysis, and writing\u2014review andediting. All authors have read and approved the final version of the manuscript and agree to be accountable for all aspects ofthe work.","order":1,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Samuel Wilkinson has received contract research funding (administered through Yale University) from Oui Therapeutics, Neurocrine Biosciences, and NRX Pharmaceuticals. He has served as a consultant or provided data safety and monitoring board services for Atai-Beckley, Joyous, LivaNova, Definium Therapeutics, Neumora, Sooma Medical, Osmind, EPIC, and Sage Therapeutics. Morgan Hardy has contract research funding from Otsuka Precision Health (administered through Yale University). Alana King and Taeho Greg Rhee declare no relevant financial or nonfinancial interests.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript is a review article and did not involve the collection of data from human participants or animals.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript is a review article; all data discussed are available in the cited publications, clinical trial registry entries, and press releases referenced in the manuscript.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}